



Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G

NUMBER OF SHARES	5	Sole Voting Power	1,538,218
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	Shared Voting Power	0
	7	Sole Dispositive Power	1,538,218
	8	Shared Dispositive Power	0
9	Aggregate Amount Beneficially Owned by Each Reporting Person		1,538,218
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares		[ ]
11	Percent of Class Represented by Amount in Row 9		5.3%
12	Type of Reporting Person		00

CUSIP No. 09058V-10-3                      SCHEDULE 13G                      Page 3 of 11

1	Name of Reporting Person		PAUL H. STEPHENS
	IRS Identification No. of Above Person		
2	Check the Appropriate Box if a member of a Group		(a) [ ]
			(b) [ ]
3	SEC USE ONLY		
4	Citizenship or Place of Organization		UNITED STATES
NUMBER OF SHARES	5	Sole Voting Power	1,793,218
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	Shared Voting Power	0
	7	Sole Dispositive Power	1,793,218
	8	Shared Dispositive Power	0
9	Aggregate Amount Beneficially Owned by Each Reporting Person		1,793,218
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares		[ ]
11	Percent of Class Represented by Amount in Row 9		6.1%
12	Type of Reporting Person		IN/HC

CUSIP No. 09058V-10-3                      SCHEDULE 13G                      Page 4 of 11

1	Name of Reporting Person		P. BARTLETT STEPHENS
	IRS Identification No. of Above Person		
2	Check the Appropriate Box if a member of a Group		(a) [ ]

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G

(b) [ ]

3 SEC USE ONLY

4 Citizenship or Place of Organization UNITED STATES

NUMBER OF SHARES	5	Sole Voting Power	1,538,218
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	Shared Voting Power	0
	7	Sole Dispositive Power	1,538,218
	8	Shared Dispositive Power	0

9 Aggregate Amount Beneficially Owned by Each Reporting Person 1,538,218

10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]

11 Percent of Class Represented by Amount in Row 9 5.3%

12 Type of Reporting Person IN/HC

CUSIP No. 09058V-10-3 SCHEDULE 13G Page 5 of 11

1 Name of Reporting Person W. BRADFORD STEPHENS

IRS Identification No. of Above Person

2 Check the Appropriate Box if a member of a Group (a) [ ]

(b) [ ]

3 SEC USE ONLY

4 Citizenship or Place of Organization UNITED STATES

NUMBER OF SHARES	5	Sole Voting Power	1,538,218
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	Shared Voting Power	0
	7	Sole Dispositive Power	1,538,218
	8	Shared Dispositive Power	0

9 Aggregate Amount Beneficially Owned by Each Reporting Person 1,538,218

10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]

11 Percent of Class Represented by Amount in Row 9 5.3%

12 Type of Reporting Person IN/HC

CUSIP No. 09058V-10-3 SCHEDULE 13G Page 6 of 11

Item 1(a). Name of Issuer:

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G

Biocryst Pharmaceuticals, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

2190 Parkway Lake Drive  
Birmingham, AL 35244

Item 2(a). Names of Persons Filing:

Stephens Investment Management, LLC ("SIM")  
  
Paul H. Stephens ("Paul Stephens")  
  
P. Bartlett Stephens ("Bart Stephens")  
  
W. Bradford Stephens ("Brad Stephens")

Item 2(b). Address of Principal Business Office or, if none, Residence:

The principal business address of each reporting person is One Sansome Street, Suite 2900, San Francisco, CA 94104.

Item 2(c). Citizenship:

Reference is made to Item 4 of pages 2-5 of this Schedule 13G (this "Schedule"), which Items are incorporated by reference herein.

Item 2(d). Title of Class of Securities:

Common Stock, \$.01 par value

Item 2(e). CUSIP Number:

09058V-10-3

Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

CUSIP No. 09058V-10-3

SCHEDULE 13G

Page 7 of 11

(d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e)  An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);

(f)  An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G

(g) [ ] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Reference is hereby made to Items 5-9 and 11 of pages 2-5 of this Schedule, which Items are incorporated by reference herein.

Paul Stephens holds 255,000 shares of the Issuer's common stock personally. The balance of shares reported as beneficially owned by the reporting persons on this Schedule are held in client accounts.

SIM, as general partner and investment manager of certain client accounts, may be deemed to have the power to direct the voting or disposition of the Issuer's common stock held by such accounts. Therefore, SIM, as those accounts' general partner and investment manager, and Paul Stephens, Brad Stephens and Bart Stephens, as managing members and owners of SIM, may be deemed to beneficially own the common stock owned by those accounts for the purposes of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, insofar as they may be deemed to have the power to direct the voting or disposition of that common stock.

CUSIP No. 09058V-10-3

SCHEDULE 13G

Page 8 of 11

Neither the filing of this Schedule nor any of its contents shall be deemed to constitute an admission that SIM, Paul Stephens, Brad Stephens or Bart Stephens is, for any other purpose, the beneficial owner of any securities to which this Schedule relates, and each of SIM, Paul Stephens, Brad Stephens and Bart Stephens disclaims beneficial ownership as to those securities, except to the extent of his or its pecuniary interests therein. Neither the filing of this Schedule nor any of its contents shall be deemed to constitute an admission that any of the other individual general partners, directors, executive officers, and members of SIM is, for any purpose, the beneficial owner of any of the securities to which this Schedule relates, and such beneficial ownership is expressly disclaimed.

The calculation of percentage of beneficial ownership in item 11 of pages 2-5 was derived from the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2006, in which the Issuer stated that the number of shares of common stock, \$.01 par value, outstanding as of November 1, 2006 was 29,233,888.

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

SIM serves as general partner and investment manager to certain client accounts that have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Issuer's common stock. Other than as reported in this Schedule, no individual client's holdings exceed five percent of that common stock.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

CUSIP No. 09058V-10-3

SCHEDULE 13G

Page 9 of 11

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 9, 2007

STEPHENS INVESTMENT MANAGEMENT, LLC

By: /s/ W. Bradford Stephens

-----  
W. Bradford Stephens  
Its Managing Member

/s/ W. Bradford Stephens

-----  
W. Bradford Stephens

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form SC 13G

/s/ P. Bartlett Stephens  
-----  
P. Bartlett Stephens

/s/ Paul H. Stephens  
-----  
Paul H. Stephens

CUSIP No. 09058V-10-3                      SCHEDULE 13G                      Page 10 of 11

EXHIBIT INDEX

Exhibit A                      Joint Filing Undertaking                      Page 11

CUSIP No. 09058V-10-3                      SCHEDULE 13G                      Page 11 of 11

EXHIBIT A

JOINT FILING UNDERTAKING

The undersigned, being authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule, as it may be amended, jointly on behalf of each of such parties.

Dated: February 9, 2007                      STEPHENS INVESTMENT MANAGEMENT, LLC

By: /s/ W. Bradford Stephens  
-----  
W. Bradford Stephens  
Its Managing Member

/s/ Paul H. Stephens  
-----  
Paul H. Stephens

/s/ W. Bradford Stephens  
-----  
W. Bradford Stephens

/s/ P. Bartlett Stephens  
-----  
P. Bartlett Stephens